244 related articles for article (PubMed ID: 24896203)
21. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A
Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074
[TBL] [Abstract][Full Text] [Related]
22. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
[TBL] [Abstract][Full Text] [Related]
23. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
[TBL] [Abstract][Full Text] [Related]
24. Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism.
Traub-Weidinger T; Putzer D; von Guggenberg E; Dobrozemsky G; Nilica B; Kendler D; Bale R; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1995-2001. PubMed ID: 26173620
[TBL] [Abstract][Full Text] [Related]
25. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
[TBL] [Abstract][Full Text] [Related]
26. ⁶⁸Ga-DOTA⁰-Tyr³-octreotide positron emission tomography in head and neck squamous cell carcinoma.
Schartinger VH; Dudás J; Decristoforo C; Url C; Schnabl J; Göbel G; Virgolini IJ; Riechelmann H; Rasse M; Waitz D; Putzer D
Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1365-72. PubMed ID: 23685751
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis.
Treglia G; Castaldi P; Rindi G; Giordano A; Rufini V
Endocrine; 2012 Aug; 42(1):80-7. PubMed ID: 22350660
[TBL] [Abstract][Full Text] [Related]
28. Positron emission tomography evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model.
Petersen AL; Binderup T; Jølck RI; Rasmussen P; Henriksen JR; Pfeifer AK; Kjær A; Andresen TL
J Control Release; 2012 Jun; 160(2):254-63. PubMed ID: 22245688
[TBL] [Abstract][Full Text] [Related]
29. Gene transcript analysis blood values correlate with ⁶⁸Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status.
Bodei L; Kidd M; Modlin IM; Prasad V; Severi S; Ambrosini V; Kwekkeboom DJ; Krenning EP; Baum RP; Paganelli G; Drozdov I
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1341-52. PubMed ID: 25947577
[TBL] [Abstract][Full Text] [Related]
30. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy.
Srirajaskanthan R; Kayani I; Quigley AM; Soh J; Caplin ME; Bomanji J
J Nucl Med; 2010 Jun; 51(6):875-82. PubMed ID: 20484441
[TBL] [Abstract][Full Text] [Related]
31. ⁶⁸Ga-DOTA-TOC-PET/CT detects heart metastases from ileal neuroendocrine tumors.
Calissendorff J; Sundin A; Falhammar H
Endocrine; 2014 Sep; 47(1):169-76. PubMed ID: 24272595
[TBL] [Abstract][Full Text] [Related]
32. Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE.
Velikyan I; Xu H; Nair M; Hall H
Nucl Med Biol; 2012 Jul; 39(5):628-39. PubMed ID: 22336375
[TBL] [Abstract][Full Text] [Related]
33. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours.
Hofman MS; Kong G; Neels OC; Eu P; Hong E; Hicks RJ
J Med Imaging Radiat Oncol; 2012 Feb; 56(1):40-7. PubMed ID: 22339744
[TBL] [Abstract][Full Text] [Related]
34. ⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET.
Ambrosini V; Campana D; Tomassetti P; Fanti S
Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S52-60. PubMed ID: 22388622
[TBL] [Abstract][Full Text] [Related]
35. 68Ga-DOTA-peptides in the diagnosis of NET.
Ambrosini V; Fanti S
PET Clin; 2014 Jan; 9(1):37-42. PubMed ID: 25029932
[TBL] [Abstract][Full Text] [Related]
36. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ
J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
[TBL] [Abstract][Full Text] [Related]
37. PET and PET/CT with 68gallium-labeled somatostatin analogues in Non GEP-NETs Tumors.
Sollini M; Erba PA; Fraternali A; Casali M; Di Paolo ML; Froio A; Frasoldati A; Versari A
ScientificWorldJournal; 2014; 2014():194123. PubMed ID: 24693229
[TBL] [Abstract][Full Text] [Related]
38. Gallium-68 PET: a new frontier in receptor cancer imaging.
Al-Nahhas A; Win Z; Szyszko T; Singh A; Nanni C; Fanti S; Rubello D
Anticancer Res; 2007; 27(6B):4087-94. PubMed ID: 18225576
[TBL] [Abstract][Full Text] [Related]
39. The untapped potential of Gallium 68-PET: the next wave of ⁶⁸Ga-agents.
Smith DL; Breeman WA; Sims-Mourtada J
Appl Radiat Isot; 2013 Jun; 76():14-23. PubMed ID: 23232184
[TBL] [Abstract][Full Text] [Related]
40. PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas.
Henze M; Schuhmacher J; Hipp P; Kowalski J; Becker DW; Doll J; Mäcke HR; Hofmann M; Debus J; Haberkorn U
J Nucl Med; 2001 Jul; 42(7):1053-6. PubMed ID: 11438627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]